NCT06951217Phase 2Recruiting

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Study sponsor: Avalyn Pharma Inc. · AVLN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2031-12-31Estimated
Enrollment · participants340Estimated
Source updated2026-11-05Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview